Setrusumab clinical trials
Also written BPS804 and UX143.
How each study uses setrusumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2013 | 1 |
| 2017 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test setrusumab, phase 3 first.
- Jan 2027Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaPhase 3 · Ultragenyx Pharmaceutical Inc
Studies
Open first, then newest update. How each study uses setrusumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaActive, not recruitingPhase 3Ultragenyx Pharmaceutical IncNCT05768854Written as Setrusumab
- Setrusumab vs Placebo for Osteogenesis ImperfectaActive, not recruitingPhase 2/3Ultragenyx Pharmaceutical IncNCT05125809Written as Setrusumab
- Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaActive, not recruitingPhase 3Ultragenyx Pharmaceutical IncNCT06636071Written as setrusumab
- Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaTerminatedPhase 2Ultragenyx Pharmaceutical IncNCT05312697Written as Setrusumab
- A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804CompletedPhase 2Ultragenyx Pharmaceutical IncNCT03118570Written as setrusumab
- An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis ImperfectaWithdrawnPhase 2Ultragenyx Pharmaceutical IncNCT03216486Written as BPS804
- Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)CompletedPhase 2Ultragenyx Pharmaceutical IncNCT01406977Written as BPS804
- Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral DensityCompletedPhase 2Ultragenyx Pharmaceutical IncNCT01406548Written as BPS804 20mg/Kg
- Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney DiseaseWithdrawnPhase 2Ultragenyx Pharmaceutical IncNCT01806610Written as BPS804
- Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis ImperfectaCompletedPhase 2Ultragenyx Pharmaceutical IncNCT01417091Written as BPS804
Codes
What other systems call setrusumab · ClinicalTrials.gg INT000786
- MeSH (NLM) C000622723setrusumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) FPW3780T3ESETRUSUMABConfirmed FDA, NLM
- NCI Thesaurus C152352SetrusumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622723 | setrusumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | FPW3780T3E | SETRUSUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C152352 | Setrusumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.